Pacira Pharmaceuticals Stock Options
| PCRX Stock | USD 25.90 0.91 3.39% |
Pacira Pharmaceuticals' option chain provides insight into all available option contracts written on Pacira Pharmaceuticals' stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of Pacira Pharmaceuticals' stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given Pacira option contract.
In The Money vs. Out of Money Option Contracts on Pacira Pharmaceuticals
Analyzing Pacira Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in Pacira Pharmaceuticals regardless of its overall volatility. This is especially true when Pacira Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Pacira Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Pacira Pharmaceuticals' stock while costing only a fraction of its price.
Pacira Pharmaceuticals' latest option contracts expiring on 2024-05-17 are carrying combined implied volatility of 58.35 with a put-to-call open interest ratio of 0.62 over 30 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on 2024-05-17. The current put volume is at 0, with calls trading at the volume of 3. This yields a 0.0 put-to-call volume ratio. The Pacira Pharmaceuticals option chain provides detailed quote and price information for the current Pacira Pharmaceuticals option contracts. It shows all of Pacira Pharmaceuticals' listed puts, calls, expiration dates, strike prices, and other pricing information.
Open Interest Against 2024-05-17 Option Contracts
Pacira Pharmaceuticals option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Pacira Pharmaceuticals' lending market. For example, when Pacira Pharmaceuticals' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Pacira Pharmaceuticals, he or she must hedge the risk by shorting Pacira Pharmaceuticals stock over its option's life.
2024-05-17
The chart above shows Pacira Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Pacira Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Pacira Pharmaceuticals' option, there is no secondary market available for investors to trade.
Pacira Pharmaceuticals Maximum Pain Price across 2024-05-17 Option Contracts
Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Pacira Pharmaceuticals close to expiration to expire worthless. According to most research, approximately 10% to 15% of all stock options are exercised, while about 35% expire worthlessly, with roughly 50% traded out before the expiration date. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Pacira Pharmaceuticals' stock options are financial instruments that give investors the right to buy or sell shares of Pacira Pharmaceuticals common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Pacira stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Pacira Pharmaceuticals' stock price goes up or down, the stock options follow.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. Please note that buying 'in-the-money' options on Pacira Pharmaceuticals lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Pacira Pharmaceuticals' value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Pacira Pharmaceuticals contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Pacira Stock moves the wrong way.
At this time, Pacira Pharmaceuticals' Total Stockholder Equity is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 1.7 B in 2024, whereas Common Stock Total Equity is likely to drop slightly above 32.8 K in 2024. Pacira Pharmaceuticals In The Money Call Balance
When Pacira Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Pacira Pharmaceuticals stock is said to be in the money. When it comes to buying Pacira Pharmaceuticals' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Pacira Pharmaceuticals are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Pacira Current Options Market Mood
Pacira Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Pacira Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of Pacira Pharmaceuticals' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Pacira Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current Pacira Pharmaceuticals' option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.
Rule 16 of the current Pacira contract
Base on the Rule 16, the options market is currently suggesting that Pacira Pharmaceuticals will have an average daily up or down price movement of about 3.65% per day over the life of the 2024-05-17 option contract. With Pacira Pharmaceuticals trading at USD 25.9, that is roughly USD 0.94. If you think that the market is fully incorporating Pacira Pharmaceuticals' daily price movement you should consider buying Pacira Pharmaceuticals options at the current volatility level of 58.35%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Pacira |
Purchasing Pacira Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Pacira calls. Remember, the seller must deliver Pacira Pharmaceuticals stock to the call owner when a call is exercised.
Pacira Pharmaceuticals Option Chain
When Pacira Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Pacira Pharmaceuticals stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Pacira Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on Pacira. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Pacira. It also shows strike prices and maturity days for a Pacira Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Delta | Gamma | Open Int | Expiration | Current Spread | Last Price | |||
Call | 2024-05-17 CALL at $15.0 | 0.9596 | 0.0086 | 0 | 2024-05-17 | 9.6 - 14.5 | 0.0 | In |
Call | 2024-05-17 CALL at $17.5 | 0.9497 | 0.0135 | 0 | 2024-05-17 | 7.1 - 12.0 | 0.0 | In |
Call | 2024-05-17 CALL at $20.0 | 0.9353 | 0.0224 | 0 | 2024-05-17 | 4.6 - 9.5 | 0.0 | In |
Call | 2024-05-17 CALL at $22.5 | 0.983 | 0.0183 | 0 | 2024-05-17 | 2.1 - 6.7 | 0.0 | In |
Call | 2024-05-17 CALL at $25.0 | 0.7133 | 0.0846 | 0 | 2024-05-17 | 0.55 - 4.8 | 0.0 | In |
Call | 2024-05-17 CALL at $27.5 | 0.507 | 0.0652 | 22 | 2024-05-17 | 0.15 - 4.2 | 0.95 | Out |
Call | 2024-05-17 CALL at $30.0 | 0.3434 | 0.0642 | 51 | 2024-05-17 | 0.1 - 2.25 | 0.35 | Out |
Call | 2024-05-17 CALL at $32.5 | 0.1116 | 0.0484 | 6 | 2024-05-17 | 0.05 - 4.2 | 0.2 | Out |
Put | 2024-05-17 PUT at $50.0 | -0.7124 | 0.0186 | 0 | 2024-05-17 | 20.8 - 25.5 | 0.0 | In |
Put | 2024-05-17 PUT at $47.5 | -0.7053 | 0.0196 | 0 | 2024-05-17 | 18.1 - 23.0 | 0.0 | In |
Put | 2024-05-17 PUT at $45.0 | -0.6968 | 0.0209 | 0 | 2024-05-17 | 15.6 - 20.5 | 0.0 | In |
Put | 2024-05-17 PUT at $42.5 | -0.6867 | 0.0225 | 0 | 2024-05-17 | 13.2 - 18.0 | 0.0 | In |
Put | 2024-05-17 PUT at $40.0 | -0.9822 | 0.0085 | 0 | 2024-05-17 | 10.9 - 15.5 | 0.0 | In |
Put | 2024-05-17 PUT at $37.5 | -0.6585 | 0.0272 | 0 | 2024-05-17 | 8.1 - 13.0 | 0.0 | In |
Put | 2024-05-17 PUT at $35.0 | -0.889 | 0.0355 | 1 | 2024-05-17 | 6.3 - 10.5 | 5.9 | In |
Put | 2024-05-17 PUT at $32.5 | -0.9722 | 0.0228 | 6 | 2024-05-17 | 3.6 - 7.8 | 3.8 | In |
Put | 2024-05-17 PUT at $30.0 | -0.7092 | 0.0742 | 27 | 2024-05-17 | 1.8 - 6.0 | 1.85 | In |
Put | 2024-05-17 PUT at $27.5 | -0.4957 | 0.0663 | 16 | 2024-05-17 | 0.6 - 4.9 | 1.55 | In |
Put | 2024-05-17 PUT at $25.0 | -0.2895 | 0.0842 | 2 | 2024-05-17 | 0.15 - 1.45 | 0.73 | Out |
Put | 2024-05-17 PUT at $22.5 | -0.265 | 0.0283 | 66 | 2024-05-17 | 0.05 - 4.7 | 0.5 | Out |
Pacira Pharmaceuticals Total Stockholder Equity Over Time
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Total Stockholder Equity |
| Timeline |
Pacira Pharmaceuticals Common Stock Total Equity Over Time
The total value of common stock equity held by shareholders, representing their ownership interest in the company. Common Stock Total Equity |
| Timeline |
Pacira Total Stockholder Equity
Total Stockholder Equity |
|
Be your own money manager
Our tools can tell you how much better you can do entering a position in Pacira Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Pacira Pharmaceuticals Corporate Directors
Pacira Pharmaceuticals corporate directors refer to members of a Pacira Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Pacira Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Pacira Pharmaceuticals' board members must vote for the resolution. The Pacira Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Gary Pace | Independent Director | Profile | |
| Mark Kronenfeld | Independent Director | Profile | |
| John Longenecker | Independent Director | Profile | |
| Mark Froimson | Director | Profile |
Already Invested in Pacira Pharmaceuticals?
The danger of trading Pacira Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Pacira Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Pacira Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Pacira Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Pacira Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacira Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacira Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacira Pharmaceuticals Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 0.89 | Revenue Per Share 14.603 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0335 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.